Bausch & Lomb begins US registration program for Nicox' glaucoma drug
This article was originally published in Scrip
Executive Summary
Bausch & Lomb has confirmed the start of a Phase III clinical program, which will support the US registration of latanoprostene bunod (previously known as BOL-303259-X and NCX 116) for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.